Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs CYTK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VNDA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

VNDA Overall Winner 6-Pillar Tally: VNDA 3 – 2 CYTK (1 Tie) Matrix Metrics: VNDA 5 – 5 CYTK

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Cytokinetics Inc. (CYTK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas CYTK carries 57.6/100 (HOLD) at $53.18 (117.7x Forward P/E, -625.2% operating margin).

  • Composite vs. Pillar Nuance: While CYTK currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. VNDA 49.0/100 HOLD), VNDA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-77.6% vs. -625.2% operating margin) and revenue trajectory (+24.1% vs. +2356.5% YoY).
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile CYTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs CYTK
VNDA NASDAQ Head-to-Head Winner
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
CYTK NASDAQ
Cytokinetics Inc.
Pharmaceutical Preparations
$53.18
-5.26% 1D
Market Cap $7.8B
TTM Revenue $113M
Forward P/E 117.7x
Beta / 30D Vol 1.09β · 58% Vol
Unified Composite Score
57.6 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.9%), weak momentum, RSI 33
RSI-14: 32.6 · SMA20: $59.62 · SMA50: $63.72

6-Pillar Scorecard Institutional Category Breakdown (VNDA 3 – 2 CYTK)

Columns: Metric · VNDA · CYTK
1. Valuation Multiples VNDA
Forward P/E 103.1x 117.7x
Trailing P/E 103.1x 117.7x
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 78.5x
2. Growth & Scale CYTK
Revenue Growth (YoY) +24.1% +2356.5%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M $113M
Market Cap $238.9M $7.8B
3. Profitability & Quality VNDA
Gross Margin 93.6% N/A
Operating Margin -77.6% -625.2%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -572.1%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$589M
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $1.07B Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CYTK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 163.3% (75th %ile) 68.8% (28th %ile)
Put/Call OI Skew N/A 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (5) vs CYTK (5)
Institutional Metric VNDA CYTK Criterion Row Edge
Market Capitalization
Scale
$238.9M $7.8B Larger Scale CYTK
Trailing P/E Ratio
Valuation
103.1x 117.7x Lower Multiple VNDA
Forward P/E Ratio
Valuation
103.1x 117.7x Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% +2356.5% Higher Growth CYTK
Operating Margin (TTM)
Profitability
-77.6% -625.2% Higher Margin VNDA
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin CYTK
Return on Equity (ROE)
Capital Efficiency
-82.5% -572.1% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 1% ($53–$88) Stronger Trend VNDA
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.09β · 58% Vol Lower Realized Risk CYTK
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 57.6 / 100 (HOLD) Higher Composite CYTK
Trailing 12M Revenue (USD)
Operating Scale
$229M $113M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 78.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$589M ($1.07B Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VNDA +8.33 pp
VNDA: -5.83% · CYTK: -14.16%
3M Horizon CYTK +0.12 pp
VNDA: -30.24% · CYTK: -30.12%
6M Horizon CYTK +8.32 pp
VNDA: -37.58% · CYTK: -29.26%
1Y Horizon VNDA +6.27 pp
VNDA: -12.56% · CYTK: -18.83%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue CYTK Revenue VNDA Op. Margin CYTK Op. Margin Margin Leader
FY2018 $190M $30M 11.3% -282.3% VNDA
FY2019 $230M $30M 10.0% -368.0% VNDA
FY2020 $250M $60M 11.0% -168.3% VNDA
FY2021 $270M $70M 15.7% -264.5% VNDA
FY2022 $250M $90M 2.5% -342.8% VNDA
FY2023 $190M $10M -7.2% -6589.7% VNDA
FY2024 $200M $20M -20.5% -2902.7% VNDA
FY2025 $220M $90M -70.0% -695.4% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CYTK BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 68.8%
IV Percentile 28th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CYTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CYTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.8B market capitalization and -625.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs CYTK Key Questions & Quantitative Answers

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Cytokinetics Inc. (CYTK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas CYTK carries 57.6/100 (HOLD) at $53.18 (117.7x Forward P/E, -625.2% operating margin). Composite vs. Pillar Nuance: While CYTK currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. VNDA 49.0/100 HOLD), VNDA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-77.6% vs. -625.2% operating margin) and revenue trajectory (+24.1% vs. +2356.5% YoY). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile CYTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CYTK leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with CYTK at +2356.5% YoY revenue growth and +0.0% YoY earnings growth on $113M TTM revenue (N/A gross margin, -625.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while CYTK shifted +200.0%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CYTK.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas CYTK trades at 117.7x Forward P/E, 117.7x Trailing P/E, N/M PEG, and 78.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus CYTK (-572.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, CYTK carries 68.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.09β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.